Hangzhou Tigermed Consulting Co (SZSE:300347) Cash-to-Debt : 2.20 (As of Dec. 2023)

View and export this data going back to 2012. Start your Free Trial

What is Hangzhou Tigermed Consulting Co Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Hangzhou Tigermed Consulting Co's cash to debt ratio for the quarter that ended in Dec. 2023 was 2.20.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Hangzhou Tigermed Consulting Co could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Hangzhou Tigermed Consulting Co's Cash-to-Debt or its related term are showing as below:

SZSE:300347' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.83 Med: 1.85 Max: 26.37
Current: 2.2

During the past 13 years, Hangzhou Tigermed Consulting Co's highest Cash to Debt Ratio was 26.37. The lowest was 0.83. And the median was 1.85.

SZSE:300347's Cash-to-Debt is ranked better than
56.41% of 234 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.39 vs SZSE:300347: 2.20

Hangzhou Tigermed Consulting Co Cash-to-Debt Historical Data

The historical data trend for Hangzhou Tigermed Consulting Co's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Hangzhou Tigermed Consulting Co Cash-to-Debt Chart

Hangzhou Tigermed Consulting Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

1.88

26.37

7.21

2.81

2.20

Hangzhou Tigermed Consulting Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															2.81	2.52	2.46	2.02	2.20

Competitive Comparison of Hangzhou Tigermed Consulting Co's Cash-to-Debt

For the Diagnostics & Research subindustry, Hangzhou Tigermed Consulting Co's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hangzhou Tigermed Consulting Co's Cash-to-Debt Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Hangzhou Tigermed Consulting Co's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Hangzhou Tigermed Consulting Co's Cash-to-Debt falls into.

Hangzhou Tigermed Consulting Co Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Hangzhou Tigermed Consulting Co's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	7462.13	/	(2533.289	+	857.332)
	=	2.20

Hangzhou Tigermed Consulting Co's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	7462.13	/	(2533.289	+	857.332)
	=	2.20

Hangzhou Tigermed Consulting Co (SZSE:300347) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Hangzhou Tigermed Consulting Co Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Hangzhou Tigermed Consulting Co's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Hangzhou Tigermed Consulting Co (SZSE:300347) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Hangzhou Tigermed Consulting Co Ltd (SZSE:300347) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

HNGZY:USA 03347:Hong Kong

Address

Block 8, No. 19 Jugong Road, Room 2001-2010, 20th Floor, Xixing Sub-District, Binjiang District, Hangzhou, CHN, 310053

Website

https://www.tigermed.net

Hangzhou Tigermed Consulting Co Ltd is a China-based Contract Research Organization. The company's segment includes Clinical trial solutions and Clinical-related and laboratory services. It generates maximum revenue from the Clinical trial solutions segment. The company's offered services include bioanalytical, medical writing, biostatistics analysis, and medical imaging. The therapeutic areas of the company include Infections, Hematology, Cardiovascular, Endocrinology, Rheumatology, Nephrology, and Central Nervous System (CNS) among others.

Hangzhou Tigermed Consulting Co (SZSE:300347) Headlines

No Headlines